

Item: 11.2

REPORT CLASSIFICATION	✓	CATEGORY OF PAPER	✓
Official	✓	Proposes specific action	
Official: Sensitive Commercial		Provides assurance	✓
Official: Sensitive Personal		For information only	

BOARD

1 OCTOBER 2024

Report Title:

Quality and Safety Committee Highlight Report

Purpose of report

To provide the Board with a summary of the key points from the meeting of the Quality and Safety Committee held on 31 July 2024.

Key points

The Committee considered several issues and supporting papers at its meeting held on 31 July 2024 and the key points are summarised below.

- **Board Assurance Framework and Quality and Safety Risk Register** - The report provided the Committee with an update on the Board Assurance Framework (BAF) and an updated position on the current risks which align to the quality and safety portfolio for the reporting period 19 April 2024 to 14 June 2024.
- **Patient Safety Incident Framework (PSIRF)** - The report provided the Committee with oversight of the PSIRF Framework. The Committee were assured the ICB are working collaboratively with Trusts and the wider system to establish continuous improvement in relation to PSIRF.
- **Quality Report** - The report provided the Committee with oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South. Updates and assurance were provided on a number of areas including: the improvement work following recent digital incidents, two recent never events regarding insulin overdose and the incorporation of medicine safety operations as a result, work to strengthen All Aged Continuing Healthcare (AACC), current safeguarding demands and pressures across the system, and a forensic awareness raising project should an adult present with a suspected non-accidental injury.
- **Complaints Report** - Two complaints reports were shared with the Committee to update on the progress achieved to date and map the current common themes/issues. Consistent themes were identified primarily in relation to access to NHS dental care and CHC (Continuing Healthcare).
- **Clinical Effectiveness and Governance Subcommittee Terms of Reference** - The proposed terms of reference (ToR) for the newly established clinical effectiveness and governance subcommittee which will report into the Executive Committee and Quality and Safety Committee were presented to the Committee. This subcommittee will bring together and merge the functions of the existing medicines subcommittee and clinical effectiveness subcommittee and associated governance structures.
- **Closedown of Serious Incident Panels** - The Committee were provided with a report concerning the progress made in closing down the ICB Serious Incident Panels. The ICB inherited a

significant volume of open serious incident cases from clinical commissioning groups. This number is now at a minimum with the anticipation that the remaining caseloads will be concluded by 31st July 2024.

- **Fuller Report** - The report provided an update on the Fuller inquiry phase 1 and 2. Assurance was given to the Committee and members were specifically asked to note all providers successfully completed the seventeen recommendations and are fully compliant.
- **Maternity and Neonatal Services** The report provided the committee with a position statement on the points raised within the letter from Dame Ruth May, Chief Nursing Officer, Professor Steve Powis, National Medical Director and Dr Emily Lawson DBE, Chief Operating Officer on 15 May 2024 regarding maternity and neonatal services – listening to women and families.

The Board is asked to note that the approved minutes for the Quality and Safety Committee meeting held in May 2024 were not available for the July Board meeting due to the date of the meeting being rescheduled to 31 July 2024 to enable quoracy to be achieved, although a highlight report was presented at the July Board meeting. The confirmed minutes are therefore also enclosed for assurance.

Risks and issues

The Committee will continue to receive and review the corporate risks aligned to the quality and safety portfolio to provide assurance to the Board that the quality and safety risks contained within the corporate risk register reflect the current environment.

Assurances

The Committee received several items for assurance including:

- Board Assurance Framework and Quality & Safety risk register.
- Integrated Delivery Report – providing an overview of quality and performance, highlighting any significant changes, areas of risk and mitigating actions.
- ICB quality exception report - oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South.
- Involvement and engagement update report
- Complaints report
- Closedown of Serious Incident Panels
- Fuller Report
- Maternity and Neonatal services Report
- Learning Disability and Autism Network update report to provide assurance it is in line with national and ICB strategic plans.
- Cancer Alliance update to highlight the Northern Cancer Alliance workplan for 2024/25, and to share achievements to date.
- Healthcare acquired infection subcommittee minutes.
- Special Educational Needs and Disabilities subcommittee minutes
- Safeguarding Health Executive minutes.
- Medicines subcommittee minutes.
- Patient voice Group minutes.
- Area quality and safety subcommittee minutes.
- System Quality Group confirmed minutes.

Recommendation/action required

The Board is asked to note the key highlights from the meeting held on 31 July 2024 and the approved minutes from this meeting.

The Board is also asked to note the approved minutes from the meeting held on 09 May 2024 for assurance.

Acronyms and abbreviations explained

As described in the report.						
Sponsor/approving executive director	Sir Pali Hungin, Chair of Quality and Safety Committee and Independent Non Executive Member David Purdue, Chief Nurse, AHP and People Officer					
Date approved by executive director	13 September 2024					
Report author	Neil Hawkins, Strategic Head of Corporate Governance					
Link to ICP strategy priorities (please tick all that apply)						
Longer and Healthier Lives						✓
Fairer Outcomes for All						✓
Better Health and Care Services						✓
Giving Children and Young People the Best Start in Life						✓
Relevant legal/statutory issues						
Note any relevant Acts, regulations, national guidelines etc						
Any potential/actual conflicts of interest associated with the paper? (please tick)	Yes		No	✓	N/A	
If yes, please specify						
Equality analysis completed (please tick)	Yes		No		N/A	✓
If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick)	Yes		No		N/A	✓
Key implications						
Are additional resources required?	None at this stage					
Has there been/does there need to be appropriate clinical involvement?	Appropriate clinical representation within the membership of the Committee. Terms of reference to include representation from Nursing Directors and Medical Directors.					
Has there been/does there need to be any patient and public involvement?	N/A.					
Has there been/does there need to be partner and/or other stakeholder engagement?	N/A					
Has there been/does there need to be appropriate finance or digital involvement?	N/A					